Stockreport

ALX Oncology: Evorpacept For ASPEN-09 Presses On With 2 Key Milestones [Seeking Alpha]

ALX Oncology Holdings Inc.  (ALXO) 
PDF ALXO pivots to targeting HER2-positive cancer patients with high CD47 expression, supported by prior studies showing higher ORR in this subgroup. Phase 2 ASPEN-09-Bre [Read more]